ELX 02

Drug Profile

ELX 02

Alternative Names: ELX-02

Latest Information Update: 09 Nov 2016

Price : $50

At a glance

  • Originator Technion - Israel Institute of Technology
  • Developer Eloxx Pharmaceuticals
  • Class Aminoglycosides; Small molecules
  • Mechanism of Action Ribosomal protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis I
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Mucopolysaccharidosis I
  • Preclinical Cystic fibrosis; Cystinosis; Rett syndrome

Most Recent Events

  • 09 Nov 2016 Preclinical trials in Cystic fibrosis in Israel (unspecified route) (Eloxx Pharmaceuticals pipeline, November 2016)
  • 09 Nov 2016 Preclinical trials in Cystinosis in Israel (unspecified route) (Eloxx Pharmaceuticals pipeline, November 2016)
  • 09 Nov 2016 Preclinical trials in Rett syndrome in Israel (unspecified route) (Eloxx Pharmaceuticals pipeline, November 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top